CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Ke Xu Sara C Meyer Franck Rapaport |
| Publication date | July 1, 2015 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |